RxDoctor Payments Data

Margaret Sutton, MD

Dermatology · Lincoln, NENPI 1043218225

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,134 of the $6,918 with a category attached, or 88.7%. AbbVie accounts for 88.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $3,538 and has fallen 73.3% since, to $944 in 2025.

$6,918in general payments, 2019–2025

Across 58 payments — averaging $119.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Galderma Laboratories, L.p.$228
  • Sun Pharmaceutical Industries Inc.$138
  • Lilly USA, LLC$84
  • Amgen$53
  • Arcutis Biotherapeutics, Inc.$46
  • plus $277 from 9 others

What the payments were for

  • Speaking & faculty fees$6,13489%
  • Food & beverage$68410%
  • Education$1001%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,918 in reported general payments places this provider in the 75th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska

Medicare billing

Part B allowed, 2024
$466,728
Medicare patients
3,372
Services billed
9,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx (2 Syringes)Secukinumab13$93,646
Dupixent PenDupilumab20$78,475
OtezlaApremilast11$52,756
Fluorouracil60$4,735
Clobetasol Propionate70$2,639
Triamcinolone Acetonide184$2,400
Betamethasone Dipropionate50$2,092
Metronidazole27$2,044
Fluocinolone Acetonide42$1,948
Minocycline Hcl60$1,851
Clindamycin Phosphate41$1,695
Ketoconazole100$1,211
Imiquimod31$1,130
Spironolactone38$816
Doxycycline Hyclate36$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$53$52,75611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 dermatology providers in Nebraska.

Other dermatology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →